市場調查報告書

全球臨床營養市場:按路線,應用和最終用戶劃分的機會分析和行業預測(2019-2026)

Clinical Nutrition Market by Route of Administration, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2019-2026

出版商 Allied Market Research 商品編碼 948567
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
全球臨床營養市場:按路線,應用和最終用戶劃分的機會分析和行業預測(2019-2026) Clinical Nutrition Market by Route of Administration, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2019-2026
出版日期: 2020年05月01日內容資訊: 英文
簡介

2018年,全球臨床營養市場規模為313,578百萬美元。預計該市場在2019年至2026年之間的複合年增長率為5.3%,到2026年將達到5255.03億美元。隨著諸如炎症性腸病和糖尿病以及與生活方式有關的疾病的慢性疾病的增加,對臨床營養的需求也在增加。這是推動人口老齡化和嬰兒潮一代增長,政府在醫療領域研發投入增加以及該市場增長的因素。此外,在亞太地區和拉丁美洲,中東和非洲等新興國家,臨床營養的進步和對臨床營養的需求不斷增加,預計將為公司進入市場提供有利的機會。但是,缺乏認識和嚴格的監管限制了市場的增長。

本報告調查了全球臨床營養市場,包括市場機會和影響,增長和限制,按管理途徑/應用/最終用戶/地區進行的市場分析,競爭格局以及主要公司的概況。

內容

第1章簡介

第2章執行摘要

第3章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資產品
  • 市場動態
    • 生長因子
      • 慢性病和與生活方式有關的疾病的發病率上升
      • 世界老年人口迅速增加
    • 抑制因子
      • 對臨床營養缺乏認識
    • 市場機會
      • 新興國家的各種增長機會

第4章市場分析:按管理途徑

  • 概述
    • 市場規模和預測
      • 經口部
      • 經腸內
      • 非經口部

第5章市場分析:按用途

  • 概述
    • 市場規模和預測
      • 癌症
      • 神經系統疾病
      • 胃腸道疾病
      • 代謝紊亂
      • 其他

第6章市場分析:按最終用戶

  • 概述
    • 市場規模和預測
      • 兒童
      • 成人
      • 老人

第7章按地區進行市場分析

  • 概述
    • 市場規模和預測
      • 北美
      • 歐洲
      • 亞太地區
      • 拉丁美洲/中東/非洲

第8章公司簡介

  • Abbott Laboratories
  • B. BRAUN MELSUNGEN AG
  • BAXTER INTERNATIONAL INC.
  • Danone Nutricia
  • Fresenius SE & Co. KGaA
  • Hero Nutritionals Inc.
  • Lonza Ltd.
  • NESTLE S.A.
  • PERRIGO COMPANY PLC
  • Pfizer Inc.
目錄
Product Code: A00717

Title:
Clinical Nutrition Market by Route of Administration (Oral, Enteral, and Parenteral), Application (Cancer, Neurological Diseases, Gastrointestinal Disorders, Metabolic Disorders, and Others), and End User (Pediatric, Adults, and Geriatric): Global Opportunity Analysis and Industry Forecast, 2019-2026.

The global clinical nutrition market size was valued at $313.578 billion in 2018, and is projected to reach $552.503 billion by 2026, growing at a CAGR of 5.3% from 2019-2026. Clinical nutrition product is a type of pharmaceutical product that helps to keep a patient healthy. It helps to improve the metabolic system by providing adequate supplements such as minerals, vitamins, and others. Clinical nutrition diagnose and treat diseases that affect the intake, intestinal absorption, and metabolism of constituents of the diet, and help promote health through prevention of diet-related diseases. It works in both acute and ambulatory care settings, which includes cardiac rehabilitation, renal dialysis, diabetes, pediatrics, nutrition support, cancer, trauma, wellness centers, and community-based intervention programs.

There is an increase in the demand for clinical nutrition owing to increase in chronic and lifestyle related disease such as inflammatory bowel disease and diabetes mellitus. Furthermore, rise in geriatric population and rise in population of a baby boomers further contributes to the market growth. Moreover, rise in R&D investments made by government in the healthcare sector drives the growth of the clinical nutrition market. However, lack of awareness and stringent regulations restrain the market growth. On the contrary, rise in advancements in clinical nutrition. Further, rise in demand of the clinical nutrition in the emerging countries such as Asia-Pacific and LAMEA and increase in home care usage of the nutritional products are expected to offer lucrative opportunities for the global clinical nutrition market players.

The global clinical nutrition market is segmented on the basis of route of administration, application, end user, and region. By route of administration, the market is classified into oral, enteral, and parenteral. On the basis of application, the market is categorized into cancer, neurological diseases, gastrointestinal disorders, metabolic disorders, and others. By end user, the market is segmented into pediatric, adults, and geriatric. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019-2026, which assists to identify the prevailing market opportunities.

An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.

A comprehensive analysis of the factors that drive and restrain the growth of the global clinical nutrition market is provided.

An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

KEY MARKET SEGMENTS

By Route Of Administration

  • Oral
  • Enteral
  • Parenteral

By Application

  • Cancer
  • Neurological Diseases
  • Gastrointestinal Disorders
  • Metabolic Disorders
  • Others

By End User

  • Pediatric
  • Adults
  • Geriatric

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • Spain
  • Italy
  • UK
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • India
  • China
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
  • KEY MARKET PLAYERS
  • Abbott Laboratories
  • B. Braun Melsungen AG
  • Danone Nutricia
  • Baxter International Inc.
  • Fresenius SE & Co. KGaA
  • Perrigo Company Plc
  • Pfizer Inc
  • Nestle S.A
  • Lonza Ltd
  • Hero Nutritionals Inc
  • The other players in the value chain (profiles not included in the report)
  • Quantel laser
  • Nidek CO., LTD.
  • Topcon Corporation
  • DEKA M.E.L.A. S.r.l.
  • SharpLight Technologies
  • Sciton, Inc.
  • Alma Lasers

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools & models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key Findings
    • 3.2.1.Top Investment Pockets
  • 3.3.Market dynamics
    • 3.3.1.Drivers
      • 3.3.1.1.Rise in incidence of chronic diseases and lifestyle associated disease
      • 3.3.1.2.Surge in geriatric population across the globe
    • 3.3.2.Restraint
      • 3.3.2.1.Lack of awareness for clinical nutrition
    • 3.3.3.Opportunity
      • 3.3.3.1.Various growth opportunities in emerging economies

CHAPTER 4:CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Oral
    • 4.2.1.Key market trends and opportunities
    • 4.2.2.Market size and forecast
    • 4.2.3.Market analysis, by country
  • 4.3.Enteral
    • 4.3.1.Key trends and opportunities
    • 4.3.2.Market size and forecast
    • 4.3.3.Market analysis, by country
  • 4.4.Parenteral
    • 4.4.1.Key market trends and opportunities
    • 4.4.2.Market size and forecast
    • 4.4.3.Market analysis, by country

CHAPTER 5:CLINICAL NUTRITION MARKET, BY APPLICATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Cancer
    • 5.2.1.Market size and forecast
    • 5.2.2.Market analysis, by country
  • 5.3.Neurological Diseases
    • 5.3.1.Market size and forecast
    • 5.3.2.Market analysis, by country
  • 5.4.Gastrointestinal Disorders
    • 5.4.1.Market size and forecast
    • 5.4.2.Market analysis, by country
  • 5.5.Metabolic Disorders
    • 5.5.1.Market size and forecast
    • 5.5.2.Market analysis, by country
  • 5.6.Others
    • 5.6.1.Market size and forecast
    • 5.6.2.Market analysis, by country

CHAPTER 6:CLINICAL NUTRITION MARKET, BY END USER

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Pediatric
    • 6.2.1.Market size and forecast
    • 6.2.2.Market analysis, by country
  • 6.3.Adults
    • 6.3.1.Market size and forecast
    • 6.3.2.Market analysis, by country
  • 6.4.Geriatric
    • 6.4.1.Market size and forecast
    • 6.4.2.Market analysis, by country

CHAPTER 7:CLINICAL NUTRITION MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key trends and opportunities
    • 7.2.2.market size and forecast, by country
    • 7.2.3.market size and forecast, by route of administration
    • 7.2.4.Market size and forecast, by application
    • 7.2.5.market size and forecast, by end user
    • 7.2.6.U.S.
      • 7.2.6.1.U.S. market size and forecast, by route of administration
      • 7.2.6.2.U.S. market size and forecast, by application
      • 7.2.6.3.U.S. market size and forecast, by end user
    • 7.2.7.Canada
      • 7.2.7.1.Canada market size and forecast, by route of administration
      • 7.2.7.2.Canada market size and forecast, by application
      • 7.2.7.3.Canada market size and forecast, by end user
    • 7.2.8.Mexico
      • 7.2.8.1.Mexico market size and forecast, by route of administration
      • 7.2.8.2.Mexico market size and forecast, by application
      • 7.2.8.3.Mexico market size and forecast, by end user
  • 7.3.Europe
    • 7.3.1.Key trends and opportunities
    • 7.3.2.Europe market size and forecast, by country
    • 7.3.3.Europe market size and forecast, by route of administration
    • 7.3.4.Europe market size and forecast, by application
    • 7.3.5.Europe market size and forecast, by end user
    • 7.3.6.Germany
      • 7.3.6.1.Germany market size and forecast, by route of administration
      • 7.3.6.2.Germany market size and forecast, by application
      • 7.3.6.3.Germany market size and forecast, by end user
    • 7.3.7.UK
      • 7.3.7.1.UK market size and forecast, by route of administration
      • 7.3.7.2.UK market size and forecast, by application
      • 7.3.7.3.UK market size and forecast, by end user
    • 7.3.8.Spain
      • 7.3.8.1.Spain market size and forecast, by route of administration
      • 7.3.8.2.Spain market size and forecast, by application
      • 7.3.8.3.Spain market size and forecast, by end user
    • 7.3.9.France
      • 7.3.9.1.France market size and forecast, by route of administration
      • 7.3.9.2.France market size and forecast, by application
      • 7.3.9.3.France market size and forecast, by end user
    • 7.3.10.Italy
      • 7.3.10.1.Italy market size and forecast, by route of administration
      • 7.3.10.2.Italy market size and forecast, by application
      • 7.3.10.3.Italy market size and forecast, by end user
    • 7.3.11.Rest of Europe
      • 7.3.11.1.Rest of Europe market size and forecast, by route of administration
      • 7.3.11.2.Rest of Europe market size and forecast, by application
      • 7.3.11.3.Rest of Europe market size and forecast, by end user
  • 7.4.Asia-Pacific
    • 7.4.1.Key trends and opportunities
    • 7.4.2.Asia-Pacific market size and forecast, by country
    • 7.4.3.Asia-Pacific market size and forecast, by route of administration
    • 7.4.4.Asia-Pacific market size and forecast, by application
    • 7.4.5.Asia-Pacific market size and forecast, by end user
    • 7.4.6.Japan
      • 7.4.6.1.Japan market size and forecast, by route of administration
      • 7.4.6.2.Japan market size and forecast, by application
      • 7.4.6.3.Japan market size and forecast, by end user
    • 7.4.7.China
      • 7.4.7.1.China market size and forecast, by route of administration
      • 7.4.7.2.China market size and forecast, by application
      • 7.4.7.3.China market size and forecast, by end user
    • 7.4.8.India
      • 7.4.8.1.India market size and forecast, by route of administration
      • 7.4.8.2.India market size and forecast, by application
      • 7.4.8.3.India market size and forecast, by end user
    • 7.4.9.Australia
      • 7.4.9.1.Australia market size and forecast, by route of administration
      • 7.4.9.2.Australia market size and forecast, by application
      • 7.4.9.3.Australia market size and forecast, by end user
    • 7.4.10.Rest of Asia-Pacific
      • 7.4.10.1.Rest of Asia-Pacific market size and forecast, by route of administration
      • 7.4.10.2.Rest of Asia-Pacific market size and forecast, by application
      • 7.4.10.3.Rest of Asia-Pacific market size and forecast, by end user
  • 7.5.LAMEA
    • 7.5.1.Key market trends and opportunities
    • 7.5.2.LAMEA market size and forecast, by country
    • 7.5.3.LAMEA market size and forecast, by route of administration
    • 7.5.4.LAMEA market size and forecast, by application
    • 7.5.5.LAMEA market size and forecast, by end user
    • 7.5.6.Brazil
      • 7.5.6.1.Brazil market size and forecast, by route of administration
      • 7.5.6.2.Brazil market size and forecast, by application
      • 7.5.6.3.Brazil market size and forecast, by end user
    • 7.5.7.South Africa
      • 7.5.7.1.South Africa market size and forecast, by route of administration
      • 7.5.7.2.South Africa market size and forecast, by application
      • 7.5.7.3.South Africa market size and forecast, by end user
    • 7.5.8.Saudi Arabia
      • 7.5.8.1.Saudi Arabia market size and forecast, by route of administration
      • 7.5.8.2.Saudi Arabia market size and forecast, by application
      • 7.5.8.3.Saudi Arabia market size and forecast, by end user
    • 7.5.9.Rest of LAMEA
      • 7.5.9.1.Rest of LAMEA market size and forecast, by route of administration
      • 7.5.9.2.Rest of LAMEA market size and forecast, by application
      • 7.5.9.3.Rest of LAMEA market size and forecast, by end user

CHAPTER 8:COMPANY PROFILES

  • 8.1.Abbott Laboratories
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
  • 8.2.B. BRAUN MELSUNGEN AG
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Product Portfolio
    • 8.2.5.B. BRAUN operates through the following product:
    • 8.2.6.Business performance
  • 8.3.BAXTER INTERNATIONAL INC.
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product Portfolio
    • 8.3.5.Business performance
    • 8.3.6.Key strategic moves and development
  • 8.4.Danone Nutricia
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
  • 8.5.Fresenius SE & Co. KGaA
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Business performance
  • 8.6.Hero Nutritionals Inc.
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
  • 8.7.Lonza Ltd.
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
    • 8.7.6.Key strategic moves and developments
  • 8.8.NESTLE S.A.
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
  • 8.9.PERRIGO COMPANY PLC
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
  • 8.10.Pfizer Inc.
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Business performance

LIST OF TABLES

  • TABLE 01.CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 02.ORAL CLINICAL NUTRITION MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 03.ENTERAL CLINICAL NUTRITION MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 04.PERENTERAL CLINICAL NUTRITION MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 05.CLINICAL NUTRITION MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 06.CANCER CLINICAL NUTRITION MARKET , BY REGION, 2018-2026 ($MILLION)
  • TABLE 07.NEUROLOGICAL DISEASES CLINICAL NUTRITION MARKET , BY REGION, 2018-2026 ($MILLION)
  • TABLE 08.GASTROINTESTINAL DISEASES CLINICAL NUTRITION MARKET , BY REGION, 2018-2026 ($MILLION)
  • TABLE 09.METABOLIC DISORDERS CLINICAL NUTRITION MARKET , BY REGION, 2018-2026 ($MILLION)
  • TABLE 10.OTHERS CLINICAL NUTRITION MARKET , BY REGION, 2018-2026 ($MILLION)
  • TABLE 11.CLINICAL NUTRITION MARKET, BY END USER, 2018-2026 ($MILLION)
  • TABLE 12.PEDIATRIC CLINICAL NUTRITION MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 13.ADULT CLINICAL NUTRITION MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 14.GERIATRIC CLINICAL NUTRITION MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 15.CLINICAL NUTRITION MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 16.NORTH AMERICA CLINICAL NUTRITION MARKET, BY COUNTRY, 2018-2026 ($MILLION)
  • TABLE 17.NORTH AMERICA CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 18.NORTH AMERICA CLINICAL NUTRITION MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 19.NORTH AMERICA CLINICAL NUTRITION MARKET, BY END USER, 2018-2026 ($MILLION)
  • TABLE 20.U.S. CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 21.U.S. CLINICAL NUTRITION MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 22.U.S. CLINICAL NUTRITION MARKET, BY END USER, 2018-2026 ($MILLION)
  • TABLE 23.CANADA CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 24.CANADA CLINICAL NUTRITION MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 25.CANADA CLINICAL NUTRITION MARKET, BY END USER, 2018-2026 ($MILLION)
  • TABLE 26.MEXICO CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 27.MEXICO CLINICAL NUTRITION MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 28.MEXICO CLINICAL NUTRITION MARKET, BY END USER, 2018-2026 ($MILLION)
  • TABLE 29.EUROPE CLINICAL NUTRITION MARKET, BY COUNTRY, 2018-2026 ($MILLION)
  • TABLE 30.EUROPE CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 31.EUROPE CLINICAL NUTRITION MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 32.EUROPE CLINICAL NUTRITION MARKET, BY END USER, 2018-2026 ($MILLION)
  • TABLE 33.GERMANY CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 34.GERMANY CLINICAL NUTRITION MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 35.GERMANY CLINICAL NUTRITION MARKET, BY END USER, 2018-2026 ($MILLION)
  • TABLE 36.UK CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 37.UK CLINICAL NUTRITION MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 38.UK CLINICAL NUTRITION MARKET, BY END USER, 2018-2026 ($MILLION)
  • TABLE 39.SPAIN CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 40.SPAIN CLINICAL NUTRITION MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 41.SPAIN CLINICAL NUTRITION MARKET, BY END USER, 2018-2026 ($MILLION)
  • TABLE 42.FRANCE CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 43.FRANCE CLINICAL NUTRITION MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 44.FRANCE CLINICAL NUTRITION MARKET, BY END USER, 2018-2026 ($MILLION)
  • TABLE 45.ITALY CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 46.ITALY CLINICAL NUTRITION MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 47.ITALY CLINICAL NUTRITION MARKET, BY END USER, 2018-2026 ($MILLION)
  • TABLE 48.REST OF EUROPE CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 49.REST OF EUROPE CLINICAL NUTRITION MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 50.REST OF EUROPE CLINICAL NUTRITION MARKET, BY END USER, 2018-2026 ($MILLION)
  • TABLE 51.ASIA-PACIFIC CLINICAL NUTRITION MARKET, BY COUNTRY, 2018-2026 ($MILLION)
  • TABLE 52.ASIA-PACIFIC CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 53.ASIA-PACIFIC CLINICAL NUTRITION MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 54.ASIA-PACIFIC CLINICAL NUTRITION MARKET, BY END USER, 2018-2026 ($MILLION)
  • TABLE 55.JAPAN CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 56.JAPAN CLINICAL NUTRITION MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 57.JAPAN CLINICAL NUTRITION MARKET, BY END USER, 2018-2026 ($MILLION)
  • TABLE 58.CHINA CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 59.CHINA CLINICAL NUTRITION MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 60.CHINA CLINICAL NUTRITION MARKET, BY END USER, 2018-2026 ($MILLION)
  • TABLE 61.INDIA CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 62.INDIA CLINICAL NUTRITION MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 63.INDIA CLINICAL NUTRITION MARKET, BY END USER, 2018-2026 ($MILLION)
  • TABLE 64.AUSTRALIA CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 65.AUSTRALIA CLINICAL NUTRITION MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 66.AUSTRALIA CLINICAL NUTRITION MARKET, BY END USER, 2018-2026 ($MILLION)
  • TABLE 67.REST OF ASIA-PACIFIC CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 68.REST OF ASIA-PACIFIC CLINICAL NUTRITION MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 69.REST OF ASIA-PACIFIC CLINICAL NUTRITION MARKET, BY END USER, 2018-2026 ($MILLION)
  • TABLE 70.LAMEA CLINICAL NUTRITION MARKET, BY COUNTRY, 2018-2026 ($MILLION)
  • TABLE 71.LAMEA CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 72.LAMEA CLINICAL NUTRITION MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 73.LAMEA CLINICAL NUTRITION MARKET, BY END USER, 2018-2026 ($MILLION)
  • TABLE 74.BRAZIL CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 75.BRAZIL CLINICAL NUTRITION MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 76.BRAZIL CLINICAL NUTRITION MARKET, BY END USER, 2018-2026 ($MILLION)
  • TABLE 77.SOUTH AFRICA CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 78.SOUTH AFRICA CLINICAL NUTRITION MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 79.SOUTH AFRICA CLINICAL NUTRITION MARKET, BY END USER, 2018-2026 ($MILLION)
  • TABLE 80.SAUDI ARABIA CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 81.SAUDI ARABIA CLINICAL NUTRITION MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 82.SAUDI ARABIA CLINICAL NUTRITION MARKET, BY END USER, 2018-2026 ($MILLION)
  • TABLE 83.REST OF LAMEA CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 84.REST OF LAMEA CLINICAL NUTRITION MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 85.REST OF LAMEA CLINICAL NUTRITION MARKET, BY END USER, 2018-2026 ($MILLION)
  • TABLE 86.ABBOTT: COMPANY SNAPSHOT
  • TABLE 87.ABBOTT: OPERATING SEGMENTS
  • TABLE 88.ABBOTT: PRODUCT PORTFOLIO
  • TABLE 89.B. BRAUN: COMPANY SNAPSHOT
  • TABLE 90.B. BRAUN: OPERATING SEGMENTS
  • TABLE 91.B. BRAUN: PRODUCT PORTFOLIO
  • TABLE 01.BAXTER: COMPANY SNAPSHOT
  • TABLE 02.BAXTER: BUSINESS SEGMENT
  • TABLE 03.NUTRICIA: COMPANY SNAPSHOT
  • TABLE 04.NUTRICIA: OPERATING SEGMENTS
  • TABLE 05.NUTRICIA: PRODUCT PORTFOLIO
  • TABLE 06.FRESENIUS: COMPANY SNAPSHOT
  • TABLE 07.FRESENIUS: OPERATING SEGMENTS
  • TABLE 08.FRESENIUS: PRODUCT PORTFOLIO
  • TABLE 09.HERO: COMPANY SNAPSHOT
  • TABLE 10.HERO: OPERATING SEGMENTS
  • TABLE 11.HERO: PRODUCT PORTFOLIO
  • TABLE 12.LONZA: COMPANY SNAPSHOT
  • TABLE 13.LONZA: OPERATING SEGMENTS
  • TABLE 14.LONZA: PRODUCT PORTFOLIO
  • TABLE 15.NESTLE: COMPANY SNAPSHOT
  • TABLE 16.NESTLE: OPERATING SEGMENTS
  • TABLE 17.NESTLE: PRODUCT PORTFOLIO
  • TABLE 18.PERRIGO: COMPANY SNAPSHOT
  • TABLE 19.PERRIGO: OPERATING SEGMENTS
  • TABLE 20.PERRIGO: PRODUCT PORTFOLIO
  • TABLE 21.PFIZER: COMPANY SNAPSHOT
  • TABLE 22.PFIZER: OPERATING SEGMENTS
  • TABLE 23.PFIZER: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.CLINICAL NUTRITION MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.CLINICAL NUTRITION MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
  • FIGURE 04.COMPARATIVE SHARE ANALYSIS OF ORAL CLINICAL NUTRITION MARKET, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 05.COMPARATIVE SHARE ANALYSIS OF ENTERAL CLINICAL NUTRITION MARKET, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 06.COMPARATIVE SHARE ANALYSIS OF PERENTERAL CLINICAL NUTRITION MARKET, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 07.COMPARATIVE SHARE ANALYSIS OF CANCER CLINICAL NUTRITION MARKET , BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 08.COMPARATIVE SHARE ANALYSIS OF NEUROLOGICAL DISEASES CLINICAL NUTRITION MARKET BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 09.COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL DISEASES CLINICAL NUTRITION MARKET BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 10.COMPARATIVE SHARE ANALYSIS OF METABOLIC DISORDERS CLINICAL NUTRITION MARKET BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 11.COMPARATIVE SHARE ANALYSIS OF OTHERS CLINICAL NUTRITION MARKET BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 12.COMPARATIVE SHARE ANALYSIS OF PEDIATRIC CLINICAL NUTRITION MARKET , BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ADULT CLINICAL NUTRITION MARKET BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF GERIATRIC CLINICAL NUTRITION MARKET BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 15.ABBOTT: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 16.ABBOTT: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 17.ABBOTT: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 18.NET SALES, 2016-2018 ($MILLION)
  • FIGURE 19.B. BRAUN: NET SALES BY DIVISION, 2018 (%)
  • FIGURE 20.B. BRAUN: NET SALES BY REGION, 2018 (%)
  • FIGURE 01.NET SALES, 2016-2018 ($MILLION)
  • FIGURE 02.BAXTER: REVENUE SHARE BY BUSINESS UNIT, 2018 (%)
  • FIGURE 03.BAXTER: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 04.FRESENIUS: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 05.FRESENIUS: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 06.FRESENIUS: REVENUE SHARE BY REGION, 2018(%)
  • FIGURE 07.NET SALES, 2016-2018 ($MILLION)
  • FIGURE 08.LONZA: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 09.LONZA: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 10.NET SALES, 2016-2018 ($MILLION)
  • FIGURE 11.NESTLE: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 12.NESTLE: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 13.PERRIGO: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 14.PERRIGO: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 15.PERRIGO: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 16.PFIZER NET SALES, 2016-2018 ($MILLION)
  • FIGURE 17.PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 18.PFIZER: REVENUE SHARE BY GEOGRAPHY, 2018 (%)